March 31, 2026 
2026 Quarterly Report
(Unaudited)
 
BlackRock Health Sciences Term Trust (BMEZ)
 
Not FDIC Insured • May Lose Value • No Bank Guarantee
Schedule of Investments (unaudited)
March 31, 2026
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets)
 
Security
 
 
Shares
Value
Common Stocks
Biotechnology — 37.0%
4D Molecular Therapeutics, Inc.(a)
 
41,862
$ 389,735
AbbVie, Inc.
 
59,784
13,002,422
Abcuro, Inc., Series C(a)(b)
 
241,900
933,734
Abivax SA, ADR(a)
 
8,695
968,188
Agios Pharmaceuticals, Inc.(a)
 
99,595
3,369,299
Akeso, Inc.(a)(c)
 
204,000
3,473,489
Aktis Oncology, Inc.(a)
 
58,563
1,047,692
Allogene Therapeutics, Inc.(a)
 
348,877
851,260
Amgen, Inc.(d)
 
45,282
15,932,472
Apogee Therapeutics, Inc.(a)
 
40,862
3,439,355
Arcellx, Inc.(a)
 
31,135
3,574,921
Arcus Biosciences, Inc.(a)
 
165,805
3,581,388
Argenx SE, ADR(a)
 
11,933
8,714,073
Ascendis Pharma A/S, ADR(a)
 
4,166
952,889
Avalo Therapeutics, Inc.(a)
 
30,621
457,172
Beam Therapeutics, Inc.(a)
 
76,864
1,831,669
Bicara Therapeutics, Inc.(a)
 
52,958
1,053,335
Biogen, Inc.(a)(d)
 
137,487
25,205,492
Biohaven Ltd.(a)
 
46,808
395,996
BioMarin Pharmaceutical, Inc.(a)
 
31,662
1,788,586
BioNTech SE, ADR(a)
 
11,340
1,007,899
BridgeBio Oncology Therapeutics, Inc.(a)
 
263,669
2,359,838
Bridgebio Pharma, Inc.(a)
 
136,783
10,157,506
Bright Minds Biosciences, Inc.(a)
 
31,933
2,330,151
Cogent Biosciences, Inc.(a)
 
262,694
10,111,092
Corvus Pharmaceuticals, Inc.(a)
 
24,771
362,400
Cytokinetics, Inc.(a)
 
17,061
1,124,490
CytomX Therapeutics, Inc.(a)
 
215,748
1,014,016
Denali Therapeutics, Inc.(a)(e)
 
78,053
1,498,618
Dianthus Therapeutics, Inc.(a)
 
62,279
5,226,454
Dyne Therapeutics, Inc.(a)
 
80,931
1,467,279
Eikon Therapeutics, Inc.(a)(e)
 
121,628
1,286,824
Enanta Pharmaceuticals, Inc.(a)
 
69,729
880,677
Erasca, Inc.(a)
 
159,240
2,576,503
Exelixis, Inc.(a)
 
210,176
9,014,449
Genmab A/S(a)
 
58,159
15,663,462
Gilead Sciences, Inc.(d)
 
214,745
29,929,011
Gossamer Bio, Inc.(a)
 
60,195
19,774
Halozyme Therapeutics, Inc.(a)
 
63,226
4,086,296
Immunocore Holdings PLC, ADR(a)
 
37,226
1,122,364
Immunocore Ltd., Series C, ADR(a)
 
321,900
9,705,285
Immunome, Inc.(a)
 
71,450
1,562,611
Incyte Corp.(a)
 
40,489
3,810,825
Insmed, Inc.(a)
 
36,385
5,949,675
Intellia Therapeutics, Inc.(a)(e)
 
131,520
1,686,086
Ionis Pharmaceuticals, Inc.(a)
 
70,173
5,269,291
Kailera Therapeutics, Inc., Series B, (Acquired
10/31/25, Cost: $3,504,004)(a)(b)(f)
 
250,286
3,504,004
KalVista Pharmaceuticals, Inc.(a)
 
70,390
1,416,951
Kiniksa Pharmaceuticals International PLC(a)
 
64,037
3,083,382
Kodiak Sciences, Inc.(a)
 
21,542
821,181
Kymera Therapeutics, Inc.(a)
 
13,937
1,160,813
Moderna, Inc.(a)(d)
 
549,814
27,930,551
Monte Rosa Therapeutics, Inc.(a)
 
70,406
1,158,179
MoonLake Immunotherapeutics(a)
 
43,395
808,883
Natera, Inc.(a)
 
82,862
16,571,571
Neurocrine Biosciences, Inc.(a)
 
79,676
10,496,516
Neurogene, Inc.(a)
 
36,199
729,772
Nuvalent, Inc., Class A(a)
 
52,024
5,329,859
Security
 
 
Shares
Value
Biotechnology (continued)
ORIC Pharmaceuticals, Inc.(a)
 
99,005
$ 1,254,393
Oruka Therapeutics, Inc.(a)
 
48,426
2,375,295
Palvella Therapeutics, Inc.(a)
 
21,246
2,648,314
Protagonist Therapeutics, Inc.(a)
 
68,855
7,257,317
PTC Therapeutics, Inc.(a)
 
34,361
2,341,015
REGENXBIO, Inc.(a)
 
81,282
681,143
ReNAgade Therapeutics, Inc., Series A-2(a)(b)
 
3,584,906
13,049,058
Revolution Medicines, Inc.(a)
 
46,968
4,567,638
Rhythm Pharmaceuticals, Inc.(a)
 
111,452
9,692,980
Roivant Sciences Ltd.(a)
 
240,456
6,660,631
Sagimet Biosciences, Inc., Series A(a)(e)
 
220,227
1,150,686
Scholar Rock Holding Corp.(a)
 
30,077
1,478,585
Stoke Therapeutics, Inc.(a)
 
132,656
4,319,279
Summit Therapeutics, Inc.(a)(e)
 
116,250
2,204,100
Syndax Pharmaceuticals, Inc.(a)
 
24,320
568,115
TScan Therapeutics, Inc.(a)
 
407,010
411,080
United Therapeutics Corp.(a)
 
3,080
1,826,378
Upstream Bio, Inc.(a)
 
56,530
508,770
Vertex Pharmaceuticals, Inc.(a)
 
20,900
9,332,686
Viking Therapeutics, Inc.(a)
 
56,322
1,832,718
Viridian Therapeutics, Inc.(a)
 
173,120
3,386,227
Vor BioPharma, Inc.(a)
 
43,710
779,786
Voyager Therapeutics, Inc.(a)
 
141,787
547,298
Zealand Pharma A/S(a)
 
46,920
2,185,064
 
 
374,256,261
Health Care Equipment & Supplies — 9.9%
Abbott Laboratories(d)
 
68,889
7,072,834
Boston Scientific Corp.(a)(d)
 
151,277
9,492,632
Dexcom, Inc.(a)(d)
 
173,259
10,880,665
Edwards Lifesciences Corp.(a)(d)
 
277,879
22,252,550
EXO Imaging, Inc., (Acquired 06/24/21, Cost:
$13,225,003)(a)(b)(f)
 
22,576
8,353
Glaukos Corp.(a)
 
12,098
1,302,471
Hologic, Inc.(a)
 
137,197
10,370,721
Insulet Corp.(a)
 
21,493
4,510,091
Intuitive Surgical, Inc.(a)
 
23,573
10,866,917
Lantheus Holdings, Inc.(a)
 
48,294
3,663,100
Medline, Inc., Class A(a)
 
141,863
6,312,904
Medtronic PLC
 
115,270
9,988,146
Novocure Ltd.(a)
 
210,016
2,289,174
Nucleix Ltd., (Acquired 04/10/24, Cost:
$1,300,000)(a)(b)(f)
 
1,300
1,030,276
Nyxoah SA(a)(e)
 
112,019
327,095
 
 
100,367,929
Health Care Providers & Services(a) — 2.3%
Guardant Health, Inc.(d)
 
221,348
20,445,915
RadNet, Inc.(e)
 
46,906
2,621,576
 
 
23,067,491
Life Sciences Tools & Services — 10.9%
Agilent Technologies, Inc.
 
112,566
12,830,273
Bio-Rad Laboratories, Inc., Class A(a)(e)
 
17,608
4,908,230
Bio-Techne Corp.
 
169,594
8,862,982
Bruker Corp.
 
64,684
2,336,386
Charles River Laboratories International, Inc.(a)(e)
 
60,883
10,502,318
Danaher Corp.
 
53,519
10,147,202
Illumina, Inc.(a)
 
116,338
14,339,822
IQVIA Holdings, Inc.(a)
 
46,747
7,972,233
Lonza Group AG, Registered Shares
 
23,258
14,920,434
Qiagen NV
 
85,732
3,432,709
Tempus AI, Inc., Class A(a)(e)
 
77,823
3,519,156
2
Schedule of Investments (unaudited)(continued)
March 31, 2026
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets)
Security
 
 
Shares
Value
Life Sciences Tools & Services (continued)
Thermo Fisher Scientific, Inc.
 
15,447
$ 7,592,664
Waters Corp.(a)
 
14,015
4,173,667
Wuxi Biologics Cayman, Inc.(a)(c)
 
1,152,500
4,956,317
 
 
110,494,393
Pharmaceuticals — 23.2%
Alumis, Inc.(a)
 
101,619
2,238,667
Arvinas, Inc.(a)
 
94,854
1,005,452
AstraZeneca PLC
 
57,869
11,412,924
Axsome Therapeutics, Inc.(a)
 
28,760
4,861,015
Bristol-Myers Squibb Co.
 
177,819
10,784,722
Daiichi Sankyo Co. Ltd.
 
93,900
1,679,933
Edgewise Therapeutics, Inc.(a)(e)
 
89,151
2,808,257
Eisai Co. Ltd.
 
304,900
9,545,445
Elanco Animal Health, Inc.(a)(e)
 
210,509
5,037,480
Enliven Therapeutics, Inc.(a)
 
54,885
2,151,492
EyePoint, Inc.(a)
 
75,092
967,936
Galderma Group AG
 
29,482
5,794,206
GSK PLC
 
521,765
14,372,267
GSK PLC, ADR
 
112,532
6,210,641
Johnson & Johnson(d)
 
145,639
35,599,996
LB Pharmaceuticals, Inc.(a)
 
207,987
5,128,959
Maze Therapeutics, Inc.(a)
 
44,725
1,335,041
MBX Biosciences, Inc.(a)
 
128,549
3,837,188
Merck & Co., Inc.(d)
 
262,388
31,562,653
Novartis AG, Class N, Registered Shares
 
104,397
16,024,346
Nuvation Bio, Inc., Class A(a)
 
283,833
1,217,644
Ocular Therapeutix, Inc.(a)
 
76,913
651,453
Pfizer, Inc.
 
538,786
15,129,111
Roche Holding AG
 
42,839
17,096,653
Terns Pharmaceuticals, Inc.(a)
 
155,371
8,191,159
Teva Pharmaceutical Industries Ltd., ADR(a)
 
212,205
6,391,615
UCB SA
 
44,287
13,343,531
WaVe Life Sciences Ltd.(a)
 
96,283
698,052
 
 
235,077,838
Total Common Stocks — 83.3%
(Cost: $749,175,409)
843,263,912
 
 
 
Benefical
Interest (000)
 
Other Interests
Biotechnology(b)(f)(g) — 0.1%
Affinivax, Inc., (Acquired 08/18/22, Cost: $ —)
$
183
672,212
Amunix Pharmaceuticals, Inc., (Acquired 02/08/22,
Cost: $ —)
 
5,657
169,712
Total Other Interests — 0.1%
(Cost: $ — )
841,924
 
 
 
 
Shares
 
Preferred Securities
Preferred Stocks — 12.6%
Biotechnology(b) — 7.0%
Abcuro, Inc., Series B(a)
 
1,092,954
1,136,672
Adarx Pharamaceuticals, Inc., Series C, (Acquired
08/02/23, Cost: $7,160,001)(a)(f)
 
860,577
11,282,164
Security
 
 
Shares
Value
Biotechnology (continued)
Angitia Biopharmaceuticals Ltd., Series D, (Acquired
01/27/26, Cost: $2,923,903)(a)(f)
 
296,024
$ 2,927,677
Bright Peak Therapeutics, Inc., Series B, (Acquired
05/14/21, Cost: $8,000,004)(a)(f)
 
3,191,830
2,393,873
Cellarity, Inc., Series B, Class B, (Acquired 01/15/21,
Cost: $14,584,998)(a)(f)
 
2,430,833
5,931,233
Genesis Therapeutics, Inc., Series B, (Acquired
08/10/23, Cost: $6,999,996)(a)(f)
 
1,370,506
7,496,668
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20,
Cost: $3,561,633)(a)(f)
 
3,409,215
1,022,765
Kartos Therapeutics, Inc.(a)(f)
 
(Acquired 02/12/26, Cost: $531,322)
 
531,322
533,766
Series C, (Acquired 08/22/23, Cost: $7,539,875)
 
1,333,783
7,575,887
Series D, (Acquired 02/19/25, Cost: $2,074,436)
 
366,962
2,084,344
Laronde, Inc., Series B, (Acquired 07/28/21, Cost:
$13,498,156)(a)(f)
 
482,077
9,313,728
Mirvie, Inc.(a)
 
Series B, (Acquired 10/15/21, Cost: $6,250,000)(f)
 
2,793,833
4,134,873
Series C
 
724,806
1,630,814
NiKang Therapeutics, Inc., Series C, (Acquired
05/20/21, Cost: $7,999,996)(a)(f)
 
1,394,189
5,339,744
Numab Therapeutics AG, Series C, (Acquired
05/07/21, Cost: $9,204,219)(f)
 
1,139,305
8,107,360
 
 
70,911,568
Health Care Equipment & Supplies(a)(b)(f) — 0.8%
EXO Imaging, Inc., Series D, (Acquired 07/24/24,
Cost: $640,450)
 
1,053,928
779,907
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost:
$6,929,998)
 
2,379,480
1,570,457
Quanta Dialysis Technologies Ltd., Series D,
(Acquired 06/18/21, Cost: $14,071,890)
 
115,766,240
5,516,217
Swift Health Systems, Inc., Series D, (Acquired
08/27/21, Cost: $6,441,930)
 
2,078
4,634
 
 
7,871,215
Health Care Providers & Services — 0.5%
Everly Well, Inc., Series D, (Acquired 11/25/20, Cost:
$9,999,986)(a)(b)(f)
 
382,775
5,022,008
Life Sciences Tools & Services — 1.2%
Sartorius AG
 
47,229
11,817,487
Pharmaceuticals(a)(b)(f) — 0.8%
Insitro, Inc.
 
Series B, (Acquired 05/21/20, Cost: $5,000,000)
 
802,478
6,708,716
Series C, (Acquired 03/10/21, Cost: $3,600,018)
 
196,818
1,645,398
 
 
8,354,114
Semiconductors & Semiconductor Equipment — 2.3%
PsiQuantum Corp., Series D, (Acquired 05/21/21,
Cost: $14,999,996)(a)(b)(f)
 
571,947
23,650,008
 
127,626,400
Total Preferred Securities — 12.6%
(Cost: $172,208,659)
127,626,400
Rights
Biotechnology(b) — 0.0%
Blueprint Medicines Corp., CVR
 
36,582
36,582
Korro Bio, Inc., CVR
 
231,775
2
Schedule of Investments
3
Schedule of Investments (unaudited)(continued)
March 31, 2026
BlackRock Health Sciences Term Trust (BMEZ)
(Percentages shown are based on Net Assets)
Security
 
 
Shares
Value
Biotechnology (continued)
Mirati Therapeutics, Inc. CVR(e)
 
180,175
$ 142,338
Vigil Neuroscience, Inc., CVR
 
131,344
6,567
 
 
185,489
Health Care Equipment & Supplies — 0.0%
Abiomed, Inc., CVR(b)
 
98,636
228,836
Total Rights — 0.0%
(Cost: $250,126)
414,325
Warrants
Biotechnology — 0.0%
Goldfinch Ltd., (Issued/Exercisable 02/10/26, 1 Share
for 1 Warrant, Expires 11/20/35, Strike Price USD
1.18)(a)(b)
 
441,503
4
Total Warrants — 0.0%
(Cost: $461,242)
4
Total Long-Term Investments — 96.0%
(Cost: $922,095,436)
972,146,565
Short-Term Securities
Money Market Funds — 5.6%
BlackRock Cash Funds: Institutional, SL Agency
Shares, 3.77%(h)(i)(j)
 
7,754,002
7,755,553
BlackRock Liquidity Funds, T-Fund, Institutional
Shares, 3.55%(h)(i)
 
48,671,382
48,671,382
Total Short-Term Securities — 5.6%
(Cost: $56,426,935)
56,426,935
Total Investments — 101.6%
(Cost: $978,522,371)
1,028,573,500
Liabilities in Excess of Other Assets — (1.6)%
(15,968,671
)
Net Assets — 100.0%
$ 1,012,604,829
 
(a)
Non-income producing security.
(b)
Security is valued using significant unobservable inputs and is classified as Level 3 in the
fair value hierarchy.
(c)
Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933,
as amended. These securities may be resold in transactions exempt from registration to
qualified institutional investors.
(d)
All or a portion of the security has been pledged and/or segregated as collateral in
connection with outstanding exchange-traded options written.
(e)
All or a portion of this security is on loan.
(f)
Restricted security as to resale, excluding 144A securities. The Trust held restricted
securities with a current value of $118,425,984, representing 11.7% of its net assets as of
period end, and an original cost of $170,041,814.
(g)
Other interests represent beneficial interests in liquidation trusts and other reorganization
or private entities.
(h)
Affiliate of the Trust.
(i)
Annualized 7-day yield as of period end.
(j)
All or a portion of this security was purchased with the cash collateral from loaned
securities.
For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the period ended March 31, 2026 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows: 
Affiliated Issuer
Value at
12/31/25
Purchases
at Cost
Proceeds
from Sales
Net
Realized
Gain (Loss)
Change in
Unrealized
Appreciation
(Depreciation)
Value at
03/31/26
Shares
Held at
03/31/26
Income
Capital Gain
Distributions
from
Underlying
Funds
BlackRock Cash Funds: Institutional, SL Agency Shares
$ 4,824,349
$ 2,932,071
(a)
$ —
$ (867
)
$ —
$ 7,755,553
7,754,002
$ 10,621
(b)
$ —
BlackRock Liquidity Funds, T-Fund, Institutional Shares
17,470,438
31,200,944
(a)
—
—
—
48,671,382
48,671,382
213,625
—
 
$ (867
)
$ —
$ 56,426,935
$ 224,246
$ —
 
(a)
Represents net amount purchased (sold).
(b)
All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and
from borrowers of securities.
4
Schedule of Investments (unaudited)(continued)
March 31, 2026
BlackRock Health Sciences Term Trust (BMEZ)
 
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows: 
• Level 1 – Unadjusted price quotations in active markets/exchanges that the Trust has the ability to access for identical assets or liabilities;
• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
• Level 3 – Inputs that are unobservable and significant to the  entire fair value measurement for the asset or liability (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments).
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy.  In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy.  The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above. 
 
Level 1
Level 2
Level 3
Total
Assets
Investments 
Long-Term Investments 
Common Stocks 
Biotechnology
$ 325,742,165
$ 31,027,300
$ 17,486,796
$ 374,256,261
Health Care Equipment & Supplies
99,329,300
—
1,038,629
100,367,929
Health Care Providers & Services
23,067,491
—
—
23,067,491
Life Sciences Tools & Services
90,617,642
19,876,751
—
110,494,393
Pharmaceuticals
157,221,457
77,856,381
—
235,077,838
Other Interests
—
—
841,924
841,924
Preferred Securities
Preferred Stocks
—
11,817,487
115,808,913
127,626,400
Rights
—
—
414,325
414,325
Warrants
—
—
4
4
Short-Term Securities 
Money Market Funds
56,426,935
—
—
56,426,935
 
$752,404,990
$140,577,919
$135,590,591
$1,028,573,500
A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value: 
 
Common
Stocks
Other
Interests
Preferred
Stocks
Rights
Warrants
Total
Assets
Opening balance, as of December 31, 2025
$ 15,261,821
$ 2,156,621
$ 126,072,047
$ 412,606
$ —
$ 143,903,095
Transfers into Level 3
—
—
—
—
—
—
Transfers out of Level 3
—
—
—
—
—
—
Accrued discounts/premiums
—
—
—
—
—
—
Net realized gain (loss)
(18,325,999
)
—
—
—
—
(18,325,999
)
Net change in unrealized appreciation (depreciation)(a)
21,589,603
(1,314,697
)
(12,736,145
)
1,719
(461,237
)
7,079,243
Purchases
—
—
3,455,226
—
461,241
3,916,467
Sales
—
—
(982,215
)
—
—
(982,215
)
Closing balance, as of March 31, 2026
$ 18,525,425
$ 841,924
$ 115,808,913
$ 414,325
$ 4
$ 135,590,591
Net change in unrealized appreciation (depreciation) on investments still held at March 31, 2026(a)
$ 3,291,197
$ (1,314,697
)
$ (12,736,145
)
$ 1,719
$ (461,237
)
$ (11,219,163
)
 
(a)
Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at March 31, 2026 is
generally due to investments no longer held or categorized as Level 3 at period end.
Schedule of Investments
5
Schedule of Investments (unaudited)(continued)
March 31, 2026
BlackRock Health Sciences Term Trust (BMEZ)
 
The following table summarizes the valuation approaches used and unobservable inputs utilized by the Valuation Committee to determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon unadjusted third-party pricing information in the amount of $6. 
 
Value
Valuation
Approach
Unobservable
Inputs
Range of
Unobservable
Inputs
Utilized(a)
Weighted
Average of
Unobservable
Inputs Based
on Fair Value
Assets
 
 
 
 
Preferred Stocks
$115,808,913
Market
Revenue Multiple
1.88x-8.86x
2.64x
 
 
Volatility
60%-90%
76%
 
 
Time to Exit
1.0 -4.0 years
2.9 years
 
 
Market Adjustment Multiple
0.25x -1.80x
1.02x
 
Income
Discount Rate
4%-19%
9%
 
 
 
 
 
Common Stocks
18,525,425
Market
Revenue Multiple
1.88x
 
 
 
Volatility
60% -90%
83%
 
 
Time to Exit
1.0 -3.0 years
2.5 years
 
 
Market Adjustment Multiple
0.25x -0.85x
0.56x
 
Income
Discount Rate
19%
 
 
 
 
 
 
Other Interests
841,924
Income
Discount Rate
4% -4%
4%
 
 
 
 
 
Rights
414,323
Income
Discount Rate
4% -5%
4%
 
 
 
 
 
 
$135,590,585
 
 
 
 
 
(a)
A significant change in unobservable input could result in a correlated or inverse change in value.
 
Portfolio Abbreviation 
ADR
 American Depositary Receipt
CVR
 Contingent Value Right
6